What do systematic reviews say?

Stem cell therapy vs peripheral therapy with granulocyte colony‐stimulating factor

• Stem cell therapy for dilated cardiomyopathy 2021 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 22 participants
  Low

Stem cell therapy vs peripheral therapy with granulocyte colony‐stimulating factor

• Stem cell therapy for dilated cardiomyopathy 2021 · Cochrane Headline outcomes only
  no estimate extracted
  0 studies · 0 participants
  GRADE not reported

Stem cell therapy vs peripheral therapy with granulocyte colony‐stimulating factor

• Stem cell therapy for dilated cardiomyopathy 2021 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 155 participants
  Low

Stem cell therapy vs peripheral therapy with granulocyte colony‐stimulating factor

• Stem cell therapy for dilated cardiomyopathy 2021 · Cochrane Headline outcomes only
  no estimate extracted
  0 studies · 0 participants
  GRADE not reported

Stem cell therapy vs peripheral therapy with granulocyte colony‐stimulating factor

It is very uncertain whether stem cell therapy (any type) changes all‐cause mortality compared with peripheral therapy with granulocyte colony‐stimulating factor (very low certainty).

• Stem cell therapy for dilated cardiomyopathy 2021 · Cochrane Headline outcomes only
  RR 0.46 [0.16, 1.31]
  3 studies · 195 participants
  Very low

Stem cell therapy vs peripheral therapy with granulocyte colony‐stimulating factor

• Stem cell therapy for dilated cardiomyopathy 2021 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 60 participants
  Very low

Stem cell therapy vs control

It is very uncertain whether stem cell therapy changes all‐cause mortality compared with control (very low certainty).

• Stem cell therapy for dilated cardiomyopathy 2021 · Cochrane Headline outcomes only
  RR 0.84 [0.54, 1.31]
  7 studies · 361 participants
  Very low

Stem cell therapy vs control

• Stem cell therapy for dilated cardiomyopathy 2021 · Cochrane Headline outcomes only
  no estimate extracted
  7 studies · 361 participants
  Very low

Stem cell therapy vs control

• Stem cell therapy for dilated cardiomyopathy 2021 · Cochrane Headline outcomes only
  no estimate extracted
  5 studies · 272 participants
  Very low

Stem cell therapy vs control

• Stem cell therapy for dilated cardiomyopathy 2021 · Cochrane Headline outcomes only
  no estimate extracted
  5 studies · 230 participants
  Very low

Stem cell therapy vs control

• Stem cell therapy for dilated cardiomyopathy 2021 · Cochrane Headline outcomes only
  no estimate extracted
  6 studies · 398 participants
  Low

Stem cell therapy vs control

• Stem cell therapy for dilated cardiomyopathy 2021 · Cochrane Headline outcomes only
  no estimate extracted
  0 studies · 0 participants
  GRADE not reported

Stem cell therapy vs control

• Stem cell therapy for dilated cardiomyopathy 2021 · Cochrane Headline outcomes only
  no estimate extracted
  8 studies · 504 participants
  Low

Intervention not reported

The intervention may leads to lower mortality (all cause) Long‐term (low certainty).

• Stem cell therapy for chronic ischaemic heart disease and congestive heart failure 2016 · Cochrane Headline outcomes only
  RR 0.42 [0.21, 0.87]
  9 studies · 491 participants
  Low

Intervention not reported

• Stem cell therapy for chronic ischaemic heart disease and congestive heart failure 2016 · Cochrane Headline outcomes only
  no estimate extracted
  34 studies · 1695 participants
  GRADE not reported

Intervention not reported

The intervention may leads to lower non‐fatal myocardial infarction Long‐term (low certainty).

• Stem cell therapy for chronic ischaemic heart disease and congestive heart failure 2016 · Cochrane Headline outcomes only
  RR 0.38 [0.15, 0.97]
  5 studies · 345 participants
  Low

Intervention not reported

The intervention showed no clear difference in rehospitalisation due to heart failure Long‐term (low certainty).

• Stem cell therapy for chronic ischaemic heart disease and congestive heart failure 2016 · Cochrane Headline outcomes only
  RR 0.63 [0.36, 1.09]
  6 studies · 375 participants
  Low

Intervention not reported

The intervention may leads to lower arrhythmias Long‐term (low certainty).

• Stem cell therapy for chronic ischaemic heart disease and congestive heart failure 2016 · Cochrane Headline outcomes only
  RR 0.42 [0.18, 0.99]
  1 study · 82 participants
  Low

Intervention not reported

The intervention showed no clear difference in composite MACE Long‐term (low certainty).

• Stem cell therapy for chronic ischaemic heart disease and congestive heart failure 2016 · Cochrane Headline outcomes only
  RR 0.64 [0.38, 1.08]
  3 studies · 141 participants
  Low

Intervention not reported

• Stem cell therapy for chronic ischaemic heart disease and congestive heart failure 2016 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 25 participants
  Low